Glimet is available for oral administration in tablets containing; 250 mg Metformin Hydrochloride with 1.25 mg Glibenclamide, 500 mg Metformin Hydrochloride with 2.5 mg Glibenclamide and 500 mg Metformin Hydrochloride with 5 mg Glibenclamide.
Mechanism of Action
Glimet combines Metformin Hydrochloride and Glibenclamide, two antihyperglycemic agents with complementary mechanisms of action, to improve glycemic control in patients with type 2 diabetes.
Metformin Hydrochloride is an antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Glibenclamide appears to lower blood, glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets.
Indications and Uses
Glimet is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone.
Glimet is indicated as second-line therapy when diet, exercise, and initial treatment with a sulfonylurea or Metformin do not result in adequate glycemic control in patients with type 2 diabetes.